Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | WNT3 | P56703 | 1/20 | 0.36 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25650059 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL17113461 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL31133635 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL25321719 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL25321715 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL25920102 | 0.91 | CHRM2 (0.39) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL11917918 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL28285326 | 0.81 | CHRM2 (0.38) | CHRM2CHRM1CHRM3WNT3SFRP1 | |
| SCHEMBL625885 | 0.79 | CHRM2 (0.44) | CHRM2CHRM1CHRM3ELANEKDM4E | |
| SCHEMBL24366554 | 0.79 | CHRM2 (0.47) | CHRM2CHRM1CHRM3ELANEKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688156-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2026-02-11 | — | — | EP | disclosed |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | ANTABIO SAS (FR) | 2025-08-05 | — | — | US | disclosed |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2024-11-28 | — | — | US | disclosed |
| WO-2024201322-A1 | LACTAM-CONTAINING IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2024-10-03 | — | — | WO | disclosed |
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | ANTABIO SAS (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117384155-A | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-111954671-B | Diazabicyclooctanones as serine beta-lactamase inhibitors | 安塔比奥公司 | 2023-09-01 | — | — | CN | disclosed |
| EP-3833665-B1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2023-07-19 | — | — | EP | disclosed |
| WO-2023111181-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| US-20220289747-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | ANTABIO SAS (FR) | 2022-09-15 | — | — | US | disclosed |
| EP-3122739-B1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2019-01-16 | — | — | EP | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-9926319-B2 | Pyridyl piperidines | MERCK PATENT GMBH (DE) | 2018-03-27 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-3122739-A1 | PYRIDYL PIPERIDINES | Merck Patent GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015144290-A1 | PYRIDYL PIPERIDINES | MERCK PATENT GMBH (DE) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905286-B2 | Diazabicyclooctanones as inhibitors of serine beta-lactamases | STS, BCKDK, PEPD | CHRM2 3993/4885CHRM1 3879/4885CHRM3 4298/4885 |
| US-20240391919-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | STS, BCKDK, PEPD | CHRM2 3993/4885CHRM1 3879/4885CHRM3 4298/4885 |
| US-12378244-B2 | Diazabicyclooctanones as inhibitors of serine β-lactamases | STS, PEPD, BCKDK | CHRM2 4122/4885CHRM1 3989/4885CHRM3 4330/4885 |
| US-20220289747-A1 | DIAZABICYCLOOCTANONES AS INHIBITORS OF SERINE BETA-LACTAMASES | STS, BCKDK, PEPD | CHRM2 3925/4885CHRM1 3736/4885CHRM3 4227/4885 |
| US-20170107222-A1 | PYRIDYL PIPERIDINES | WNT1, CTNNB1, WNT3 | CHRM2 3984/4885CHRM1 3663/4885CHRM3 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.